Results to differ from expectations contemplated by forward-looking Risks and uncertainties that could cause the actual Materially from those currently anticipated due to a number of risks and Reliance on these forward-looking statements. Involve risks and uncertainties and are cautioned not to place undue Investors are cautioned that any suchįorward-looking statements are not guarantees of future performance and Integrating the companies and the accuracy of any assumptions The ability to complete the transaction considering the various closingĬonditions difficulties or unanticipated expenses in connection with Transaction the expected timing of the completion of the transaction Results from clinical trials filings and approvals relating to the Gilead to advance Kite’s product pipeline, including axi-cel, theĪnticipated timing of clinical data the possibility of unfavorable Products, approval of axi-cel by regulatory authorities, the ability of Gilead’s revenues and earnings, the commercial success of Kite’s Limitation, statements regarding the business combination, its effect on Forward-looking statements include, without Intent, belief or current expectation of Gilead and members of its Statements of historical fact are statements that could be deemedįorward-looking statements, including all statements regarding the To risks, uncertainties and other factors. This press release includes forward-looking statements that are subject Gilead has operations in more than 30Ĭountries worldwide, with headquarters in Foster City, California. Gilead’s mission is to advance the care of patients suffering from Gilead Sciences is a biopharmaceutical company that discovers, developsĪnd commercializes innovative therapeutics in areas of unmet medical For more information on Kite, please visit About Gilead Sciences Kite’s ZUMA-1 pivotal trial with axi-cel in patients withĬhemorefractory aggressive non-Hodgkin lymphoma. This submission comes after positive results from Kite received priority review on MayĢ9, 2017 with the Prescription Drug User Fee Act action date set for Refractory aggressive non-Hodgkin lymphoma who are ineligible forĪutologous stem cell transplant. Product candidate, axi-cel, as a treatment for patients with relapsed or Submitted a Biologics License Application to the FDA for its lead System’s ability to recognize and kill tumors. Receptor (TCR) engineered cell therapies designed to empower the immune The company is focused on chimeric antigen receptor (CAR) and T cell Long-term, durable response and eliminating the burden of chronic care. Innovative cancer immunotherapies with a goal of providing rapid, Kite is a biopharmaceutical company engaged in the development of Thereafter, Kite common stock will cease to be traded on Will be cancelled and converted into the right to receive the sameĬonsideration, without interest, received by holders who tendered in the Subsidiary of Gilead, and each share of Kite’s outstanding common stock Following the merger, Kite will become a wholly-owned Without a vote of Kite’s other stockholders pursuant to Section 251(h) Purchaser will acquire all of the remaining outstanding shares of KiteĬommon stock by means of a merger of Purchaser with and into Kite Purchaser, and shares held by any Kite stockholder who exercisedĪppraisal rights under Section 262 of the Delaware General Corporate Law Treasury), shares held by Gilead or any of its subsidiaries, including Tendered and not withdrawn and will promptly pay for such shares.Įligible Kite shares exclude shares held by Kite (or in Kite’s Gilead has accepted for payment all shares validly Guaranteed Delivery, representing approximately 3.46% of the shares Shares (including 2,003,002 shares delivered through Notices of Offer, representing approximately 66.20% of Kite’s currently outstanding That, as of one minute after 11:59 p.m., New York City time, on OctoberĢ, 2017, the initial expiration of the tender offer, approximatelyģ8,324,617 shares were validly tendered and not withdrawn in the tender Computershare TrustĬompany, N.A., the depositary for the tender offer, has advised Gilead Share, net to the seller in cash, without interest. (“Purchaser”), for all of the outstanding shares ofĬommon stock of Kite Pharma, Inc. (Nasdaq: GILD) today announced the successfulĬompletion of the tender offer by its wholly-owned subsidiary, Dodgers
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |